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Summary Background There remains the need for more effective therapeutic options to treat acne
vulgaris. Interest in light-based acne treatments has increased, but few randomized,
controlled clinical trials assessing the value of photodynamic therapy (PDT) for acne
have been reported.
Aims We sought to examine the efficacy of PDT using 5-aminolevulinic acid (ALA) and
pulsed dye laser therapy in the treatment of acne.
Patients ⁄ methods We conducted a randomized, controlled, split-face, single-blind clinical
trial of 44 patients with facial acne. Patients were randomized to receive three pulsed
dye laser treatments to one side of the face after a 60–90 min ALA application time,
while the contralateral side remained untreated and served as a control. Serial blinded
lesion counts and global acne severity ratings were performed.
Results Global acne severity ratings improved bilaterally with the improvement noted to
be statistically significantly greater in treated skin than in untreated skin. Erythematous
macules (remnants of previously active inflammatory lesions) decreased in number in
treated skin when compared with control skin and there was a transient but significant
decrease in inflammatory papules in treated skin when compared with untreated skin.
There were no other statistically significant differences between treated and untreated
sides of the face in terms of counts of any subtype of acne lesion. Thirty percent of
patients were deemed responders to this treatment with respect to improvement in their
inflammatory lesion counts, while only 7% of patients responded in terms of nonin-
flammatory lesion counts.
Conclusions PDT with the treatment regimen employed here may be beneficial for a
subgroup of patients with inflammatory acne.
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Introduction
Acne vulgaris is among the most common cutaneous
disorders and it is associated with the potential for
significantly disfiguring scarring and psychosocial mor-
bidity.1–3 Although many traditional oral and topical
medical agents have been demonstrated to be effective in
the treatment of acne, the prevalence of the disease and
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its frequently resistant nature make the development of
alternative therapies highly desirable.
Light-based approaches to the treatment of acne date
back many years, but recently there has been renewed
interest in this area. A number of lasers and other light
sources have been assessed as possible treatments for
acne, and several authors have reported promising
initial results.4–9 However, many of the studies reported
to date have inherent design-based limitations such as a
lack of a control group, patients being allowed to remain
on other anti-acne therapies during the course of the
studies, and low patient numbers that make statistical
analysis of the work challenging.
Pulsed dye laser therapy has been reported by some
investigators to be efficacious in the treatment of acne
vulgaris, while this has been refuted by other research-
ers.10,11 In an attempt to enhance the efficacy of these
and other visible light wavelength devices in the treat-
ment of acne, several investigators have employed a
topical photosensitizer prior to laser ⁄ light therapy.12–15
One such treatment approach that has been advo-
cated is the application of topical 20% 5-aminolevu-
linic acid used in conjunction with pulsed dye laser
therapy.16 We sought to objectively assess photo-
dynamic therapy (PDT) using this popular treatment
protocol in a randomized, blinded, split-face controlled
clinical trial.
Methods
This study was approved by the institutional review
board of the University of Michigan Medical School,
and informed consent was obtained from all study
subjects and parental consent was obtained for patients
under 18 years of age. Patient recruitment occurred
between January 2005 and January 2008, and the
study was completed in July 2008. Inclusion criteria
included an age of 13 years or older for patients of
either gender and of any racial ⁄ ethnic group. Patients
were required to have clinically evident facial acne at
the time of study entry and were felt to be in generally
good health and willing and able to comply with the
requirements of the protocol. Potential patients were
excluded from participation for the use of an oral
retinoid within 1 year, systemic acne therapies (such as
oral antibiotics) within 4 weeks, or topical acne ther-
apies including over-the-counter products or prescrip-
tion medications (retinoids, antibiotics) within 2 weeks
of entry into the study. Patients were also excluded for
a history of having undergone microdermabrasion or
superficial chemical peels at the sites to be treated
within 2 months of entry into the study or
dermabrasion or laser resurfacing at the sites to be
treated at any time. Noncompliant patients, those with
a significant medical history or concurrent illness ⁄ con-
dition that the investigators felt was not safe for study
participation, and pregnant or nursing patients were
also excluded. In addition, excluded were patients with
a history of frequent herpes simplex infections of the
face or with clinical evidence of active herpes simplex
infection, those with a history of keloid scar formation,
patients with a known allergy or hypersensitivity to
topical photosensitizing agents, and those with known
photosensitivity disorders.
The study was a randomized, controlled, split-face,
single-blind clinical trial. Patients were randomized to
receive topical photosensitizer applications followed by
pulsed dye laser therapy to one side of the face and the
contralateral side of the face remained untreated, thus
serving as an internal control. A randomized code
determined which side of each patient’s face was to be
treated. Patients received a total of up to three
treatment sessions spaced at approximately 2-week
intervals. Acetone scrubs were performed prior to the
application of 20% 5-aminolevulinic acid (Levulan,
DUSA Pharmaceuticals, Inc., Willmington, MA, USA),
which was left in place for 60–90 min prior to each
treatment. Laser therapy was performed using a pulsed
dye laser (VBeam, Candela Coroporation, Wayland,
MA, USA) using the following treatment parameters:
10-mm spot size, 10-ms pulse duration, and 6.5–
7.5 J ⁄ cm2. (Patients with Fitzpatrick types I–IV skin
were treated at 7.5 J ⁄ cm2, while those of darker skin
types were treated at lower fluences because of their
relatively increased risk of postinflammatory hyperpig-
mentation.) A single pass of minimally overlapping
pulses was applied to one side of the face. Treatment
parameters were nonpurpuric and pulse stacking was
not performed. The treating physicians (JS Orringer and
DL Sachs) were not involved in clinical evaluations of
the patients. Strict light precautions were required of
patients for at least 48 h after each treatment session.
Clinical evaluations including live lesion counts and
global grading using the modified Leeds acne severity
scale were performed at baseline and then every
2 weeks for a total of up to 16 weeks.17 Counts of
papules, pustules, cysts, open comedones, closed com-
edones, and erythematous macules were performed.
The latter category was intended to account for
inactive, resolving previously inflammatory lesions.
The Leeds scale is a 12-point ordinal photonumeric
global acne severity scale where a rating of 1 denotes
the mildest acne and a rating of 12 represents the most
severe.
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Statistical methods
For all endpoints, the change from baseline for the
treated side of the face was compared with the change
from baseline on the untreated side in all patients. The
data were analyzed with the Student’s t-test for paired
data. All P values are two-tailed. Descriptive statistics
are presented as means and their respective standard
errors. The data were analyzed with sas analytic
software (SAS Institute Inc., Cary, NC, USA).
Mixed model fitting the lesion count with covariates
age, gender, race, severity rating, continuous time,
treatment, and time–treatment interaction, with ran-
dom intercept and time was used to obtain predicted
values where data were missing. Respondents were
classified as individuals who had at least 25% fewer
lesions at week 6 on the treated side when compared
with the untreated side, and also had at least 25% fewer
lesions on the treated side at week 6 compared with
baseline lesion counts. Fisher’s exact test was performed
to check the association between the two criteria.
Logistic regression was used to check if age, gender,
race, treatment, or total number of lesions were predic-
tive of responder status. The two-sided paired t-test was
performed to compare responders and nonresponders on
baseline lesion counts by type. Analysis was performed
for responder classification based on total lesion counts,
inflammatory lesions alone (defined by the sum of
papules, pustules, and cysts), and noninflammatory
lesions alone (defined by the sum of closed and open
comedones).
Results
A total of 99 patients were screened for study partici-
pation and 44 patients were found to meet eligibility
requirements and were randomized for inclusion in the
study (Fig. 1).
Among enrolled patients, 14 were male, 30 were
female, and patients were of a mean age of 25 years
(range 15–50 years). Twenty-four patients were ran-
domized to receive treatments to the left side of the face
and 20 to the right side. A total of 29 patients completed
the entire 16-week long study and 33 presented for at
least one follow-up evaluation visit after their series of
treatments.
On week 10 of the study, there was a statistically
significant decrease from baseline in mean inflammatory
papule counts in treated skin ()4.63) when compared
with untreated skin ()0.13), P = 0.01, but this effect
was transient with no significant benefit in papule
counts noted at the conclusion of the study on week 16.
There were also no statistically significant changes from
baseline in lesion counts of any subtype of lesion when
comparing treated and untreated skin on week 16 at the
conclusion of the study, with one exception. Erythem-
atous macules decreased in number bilaterally from
baseline to week 16, but the mean lesion decrease was
statistically significantly more profound in treated skin
()5.89) when compared with untreated skin ()2.50),
P = 0.04. In general, there were mild decreases in most
subtypes of lesions (papules, pustules, open, and closed
comedones) at week 16 when compared with baseline.
However, these changes occurred bilaterally on average
such that there were no statistically significant differ-
ences in lesion counts between treated and untreated
control skin (P > 0.05). One exception to the general
trend toward bilateral improvement was a very mild
increase in cyst counts bilaterally, but the baseline and
week 16 mean cyst counts were very low (less than 1
per side on average) and this mild and statistically
nonsignificant increase was not clinically relevant.
Summary statistics of counts of all lesion subtypes are
presented in Table 1.
Global acne severity scores decreased from baseline to
week 16 bilaterally. The improvement in mean Leeds
scores was more pronounced in treated skin ()1.07)
than untreated skin ()0.52) and this difference was
statistically significant (P = 0.01).
Additional statistical analyses were carried out to
attempt to define and characterize subgroups of
patients who did respond to the therapy. Responders
were considered to be those who experienced at least a
25% decrease in lesion counts in treated skin when
Figure 1 Trial profile.
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compared with baseline and who had at least 25%
fewer lesions on the treated side of the face when
compared with untreated skin after completion of the
final treatment session at week 6. When defined in this
way, a total of 8 (18%) of patients were considered to
be responders to the treatment. Further analysis was
performed to determine whether patients with inflam-
matory or noninflammatory lesions were more likely to
respond to the treatment. In this analysis, patients were
considered responders if their inflammatory lesion
counts (papules + pustules + cysts) were found to
decrease by at least 25% as compared with baseline
in treated skin and those total counts were found to be
at least 25% lower than inflammatory lesion counts in
untreated skin. Thirteen (30%) patients were deemed
responders in this way. A similar analysis was per-
formed examining noninflammatory lesion counts
(open comedones + closed comedones). Here, only
three (7%) patients were found to have responded to
the PDT as defined above.
The treatments were generally well tolerated by
patients and adverse events were mild and few in
number. Two patients experienced mild peeling on the
treated sides of their faces, two patients experienced
transient postinflammatory hyperpigmentation in trea-
ted skin, and one patient developed a small blister on the
day after treatment. All of these side effects resolved
without permanent sequelae.
Discussion
Despite the availability of numerous effective medical
therapies for acne vulgaris, issues of safety, compliance,
and less than ideal efficacy help drive the search for
alternative treatments for this exceedingly common
clinical problem. There has been a long history of the
use of light-based treatments for acne extending back
decades wherein ultraviolet light was used to combat
this condition. In recent years, the use of lasers and
other light-based devices in the treatment of a wide
variety of dermatologic disorders has been espoused. The
boom in the use of these devices for esthetic applications
has helped bring about renewed interest in developing
effective light-based therapies for acne.
Table 1 Summary statistics of counts of all lesion subtypes at baseline, week 10, and week 16 in treated and untreated skin
Baseline (95% CI) Week 10 (95% CI) D (95% CI) P-value
Papules Treated 13.50 (9.95–17.05) 8.87 (6.98–10.75) )4.63 ()7.43 to )1.83) 0.01
Untreated 13.57 (10.59–16.55) 13.43 (10.17–16.70) )0.13 ()2.83 to 2.57)
Pustules Treated 6.40 (2.31–10.49) 4.60 (2.40–6.80) )1.80 ()5.05 to 1.45) 0.43
Untreated 6.33 (2.58–10.09) 5.13 (2.97–7.30) )1.20 ()4.49 to 2.09)
Cysts Treated 0.50 (0.09–0.91) 0.60 (0.26–0.94) 0.10 ()0.35 to 0.55) 0.79
Untreated 0.53 (0.14–0.92) 0.60 (0.29–0.91) 0.07 ()0.30 to 0.43)
Closed comedones Treated 28.93 (21.71–36.15) 23.87 (17.86–29.87) )5.07 ()10.53 to 0.40) 0.1
Untreated 30.27 (24.77–35.76) 29.10 (22.37–35.83) )1.17 ()7.52 to 5.19)
Open comedones Treated 13.13 (4.92–21.34) 12.13 (5.37–18.89) )1.00 ()6.37 to 4.37) 0.73
Untreated 14.20 (5.29–23.11) 13.57 (5.77–21.37) )0.63 ()6.01 to 4.75)
Erythematous macules Treated 23.72 (13.76–33.68) 21.84 (11.22–32.46) )1.88 ()7.73 to 3.97) 0.02
Untreated 23.36 (11.89–34.83) 24.64 (13.94–35.34) 1.28 ()4.66 to 7.22)
Severity Treated 3.63 (2.91–4.36) 2.73 (2.03–3.44) )0.90 ()1.30 to )0.50) 0.003
Untreated 3.67 (3.00–4.34) 3.37 (2.70–4.04) )0.30 ()0.65 to 0.05)
Baseline (95% CI) Week 16 (95% CI) D (95% CI) P-value
Papules Treated 13.31 (9.76–16.86) 11.52 (7.93–15.10) )1.79 ()5.98 to 2.39) 0.62
Untreated 13.66 (10.59–16.72) 12.69 (9.11–16.27) )0.97 ()4.32 to 2.39)
Pustules Treated 6.45 (2.21–10.69) 3.90 (1.89–5.91) )2.72 ()6.65 to 1.20) 0.85
Untreated 6.38 (2.49–10.27) 3.76 (2.03–5.49) )2.62 ()6.25 to 1.01)
Cysts Treated 0.45 (0.08–0.82) 0.83 (0.31–1.34) 0.38 ()0.20 to 0.96) 0.49
Untreated 0.62 (0.18–1.06) 0.86 (0.42–1.31) 0.24 ()0.33 to 0.82)
Closed comedones Treated 29.24 (21.80–36.68) 22.28 (17.22–27.33) )6.97 ()13.30 to )0.63) 0.21
Untreated 29.38 (23.48–35.28) 25.31 (20.02–30.60) )4.07 ()9.12 to 0.98)
Open comedones Treated 15.00 (5.95–24.05) 10.21 (5.09–15.33) )4.79 ()11.62 to 2.04) 0.27
Untreated 16.07 (6.55–25.59) 9.28 (3.84–14.71) )6.79 ()13.88 to 0.29)
Erythematous macules Treated 22.29 (13.07–31.50) 16.39 (10.27–22.52) )5.89 ()12.12 to 0.34) 0.04
Untreated 21.71 (11.21–32.22) 19.21 (11.82–26.61) )2.50 ()8.85 to 3.85)
Severity Treated 3.63 (2.88–4.38) 2.56 (2.7–3.04) )1.07 ()1.69 to )0.45) 0.01
Untreated 3.59 (2.94–4.25) 3.07 (2.52–3.62) )0.52 ()1.07 to 0.04)
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Prior research has suggested a potential role for
infrared and ⁄ or visible light lasers and light sources in
the treatment of acne, yet most of this published work is
in the form of small pilot studies without a randomized,
controlled design. Unfortunately, in some cases, initial
enthusiasm for a given treatment based on preliminary
or pilot study results has led to later disappointment
when larger, more rigorously designed clinical trials
have been reported. Indeed, our own work in this area
has previously demonstrated generally sub-optimal effi-
cacy with the use of either infrared or visible light lasers
for this indication.11,18
The use of topical photosensitizers to potentially
enhance the effects of light-based therapies has proved
to be a valuable strategy in the treatment of clinical
photoaging.19–21 Others have also reported on the
successful use of PDT for acne. Hongcharu and col-
leagues demonstrated significant improvement in back
acne among patients treated with aminolevulinic acid
and a noncoherent red light source, but the applicability
of the treatment to many acne patients was questioned
because of associated side effects such as hyperpigmen-
tation and crusting.14 More recently, Horfelt et al.
demonstrated a 54% decrease in inflammatory acne
lesions in treated skin when compared with a 20%
decrease in such lesions in control skin following a split-
face clinical trial of PDT using methyl aminolevulinic
acid and a noncoherent red light source.22 Similarly, the
use of ALA and a broadband light source reportedly
significantly decreased inflammatory lesion counts in a
small uncontrolled clinical trial, but those authors noted
that optimal treatment conditions and parameters have
yet to be determined.23
There has been much speculation as to mechanisti-
cally how PDT might act to clinically improve acne.
In vitro work involving a blue light source as reported
by Ashkenazi and colleagues suggested that PDT might
decrease counts of Propionibacterium acnes.24 Others
have suggested that direct injury to sebaceous glands
might underlie the clinical benefits of such treatment.6
Yet other researchers have failed to demonstrate an
impact of PDT on either P. acnes counts or sebum
production – results that clearly call into question the
potential mechanisms involved.25 We found it to be of
note that the effect of the treatment in our study
appeared to be more profound on inflammatory lesions
as opposed to noninflammatory lesions. If the mecha-
nism of action truly involves an effect on bacterial
counts or sebaceous gland structure and function, we
would have expected to see equivalent improvement
across all subtypes of acne lesions and this was clearly
not the case. One might argue that the red color of the
inflammatory lesions more efficiently absorbed the laser
light than did the noninflammatory lesions. This might
serve to make the treatment relatively more effective
for inflammatory lesions, whatever the mechanism
involved might be, but this is purely speculative. In any
case, our finding that more patients responded with
respect to their inflammatory lesion counts is in
keeping with the findings of a recent PDT consensus
panel.
It was also noteworthy that erythematous macules
cleared to a statistically significant degree in treated
skin. Again, the oxygenated hemoglobin within the
dilated vessels that produced the erythema in these
lesions might have served as a chromophore for the
pulsed dye laser light. This would account for the
preferential clearing of these remnants of previously
inflammatory lesions in skin treated with PDT.
Another notable finding was the fact that overall
mean inflammatory papule counts were found to
improve in treated skin by week 10, but that this
positive effect was no longer evident by week 16 when
counts from all patients were considered. It is possible
that temporary decreases in bacterial counts may have
contributed to this phenomenon with repopulation of
the bacteria accounting for the transient nature of the
improvement. In any case, such a finding argues for
the possible need for ongoing maintenance therapy to
sustain any clinical benefits of the treatment. In
addition, interesting in our results was the finding
that patients’ mean global acne severity scores did
decline more substantially in treated skin than in
control skin. While individual lesion counts are
perhaps the gold standard endpoint for measuring
clinical efficacy, the fact that global severity ratings
using the Leeds scale did significantly improve with
this treatment does suggest potential benefit of this
treatment regimen.
This study was limited in that it defines outcomes
for one specific, albeit clinically popular, PDT regimen.
It is possible that by varying a number of treatment
parameters (including the light source used, the
photosensitizer employed and its contact time, etc.),
more significant clinical improvements may be achiev-
able. In addition, the early withdrawal rate in this
clinical trial acts to decrease the sample size and thus
the statistical power. However, the number of partic-
ipants in this study compares favorably to most
reported clinical trials of light-based therapies for
acne. Furthermore, the current results only speak to
the level of efficacy of this treatment protocol among
our specific patient sample group. It is possible that
this form of PDT might prove to be either more or less
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effective among patients with relatively milder or more
severe acne at baseline.
Previous research involving a similar ALA and pulsed
dye laser–based approach using treatment parameters
that were nearly identical to those employed in the
current study demonstrated complete clearance of all
acne lesions among all 14 patients treated in this
fashion.16 However, subjects in that study were also
prescribed other concurrent anti-acne medications mak-
ing interpretation of the findings difficult. Unfortunately,
we were not able to duplicate these previously reported
very positive results and, in fact, only a minority of our
patients responded to the treatment in a significant
fashion. Further confounding our efforts to assess the
validity of this treatment approach was the fact that,
even among responders as defined above, we were
unable to define patient characteristics (age, baseline
acne severity, gender, etc.) that were predictive of
treatment outcomes. Our results suggest that, with the
specific treatment protocol employed in this study,
results with respect to acne improvement can be
expected to be rather modest and inconsistent. However,
the fact that some patients did improve with the current
regimen allows for the possibility that future work
examining dose response curves, optimization of light
source, definition of ideal photosensitizer application
times and conditions, and a number of other variables
might one day make PDT for acne an important
therapeutic tool. For now, our data suggest that PDT
using the pulsed dye laser is a second or third line
treatment option to be considered for patients with
inflammatory acne who have not responded to tradi-
tional medical therapies.
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